FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer

Nuclear Medicine Communications

Volumn 27, Issue 6, 2006, Pages 481-487

  Torizuka, Tatsuo ^a   Nakamura, Fumitoshi ^a   Takekuma, Munetaka ^b   Kanno, Toshihiko ^b   Ogusu, Tomomi ^b   Yoshikawa, Etsuji ^c   Okada, Hiroyuki ^c   Maeda, Makoto ^c   Ouchi, Yasuomi ^a  

^a Tokyo Metropolitan Institute of Gerontology   (Japan)

^b HAMAMATSU MEDICAL CENTER   (Japan)

^c CENTRAL RESEARCH LABORATORY   (Japan)

Author keywords

Diagnosis; FDG PET; Myometrial infiltration; Uterine corpus cancer

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CLINICAL TRIAL; FEMALE; HUMAN; METHODOLOGY; MIDDLE AGED; MYOMETRIUM; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROGNOSIS; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; UTERUS CANCER; ANALYTIC METHOD; BODY WEIGHT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTMENOPAUSE;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; MYOMETRIUM; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; UTERINE NEOPLASMS;

EID: 33746430148     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200606000-00002     Document Type: Article

References (35)

1. Bray F, Dos Santos Silva I, Moller H, Weiderpass E. Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev 2005; 14:1132-1142.
2. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
3. Rose PG. Endometrial carcinoma. N Engl J Med 1996; 335:640-649.
4. Shepherd JH. Revised FIGO staging for gynaecological cancer. J Obstet Gynaecol 1989; 96:889-892.
5. Pettersson F. International Federation of Gynecology and Obstetrics. Annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet 1991; 21:141.
6. Berman ML, Ballon SC, Lagasse LD, Watring WG. Prognosis and treatment of endometrial cancer. Am J Obstet Gynecol 1980; 136:679-688.
7. Cowles TA, Magrina JF, Masterson BJ, Capen CV. Comparison of clinical and surgical-staging in patients with endometrial carcinoma. Obstet Gynecol 1985; 66:413-416.
8. DiSaia PJ, Creasman WT, Boronow RC, Blessing JA. Risk factors and recurrent patterns in stage I endometrial cancer. Am J Obstet Gynecol 1985; 151:1009-1015.
9. Takahashi K, Yoshioka M, Kosuge H, Iizuka Y, Musha T, Yamauchi I, et al. The accuracy of computed tomography and magnetic resonance imaging in evaluating the extent of endometrial carcinoma. Nippon Sanka Fujinka Gakkai Zasshi 1995; 47:647-654.
10. Varpula MJ, Klemi PJ. Staging of uterine endometrial carcinoma with ultra-low field (0.02 T) MRI: a comparative study with CT. J Comput Assist Tomogr 1993; 17:641-647.
11. Manfredi R, Mirk P, Maresca G, Margariti PA, Testa A, Zannoni GF, et al. Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning. Radiology 2004; 231:372-378.
12. Scoutt LM, McCarthy SM, Flynn SD, Lange RC, Long F, Smith RC, et al. Clinical stage I endometrial carcinoma: pitfalls in preoperative assessment with MR imaging. Work in progress. Radiology 1995; 194:567-572.
13. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005; 23:1136-1143.
14. Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2004; 31:22-28.
15. 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 2004; 22:1253-1259.
16. Horowitz NS, Dehdashti F, Herzog TJ, Rader JS, Powell MA, Gibb RK, et al. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol 2004; 95:546-551.
17. Belhocine T, De Barsy C, Hustinx R, Willems-Foidart J. Usefulness of (18) F-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur J Nucl Med Mol Imaging 2002; 29:1132-1139.
18. Saga T, Higashi T, Ishimori T, Mamede M, Nakamoto Y, Mukai T, et al. Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer. Ann Nucl Med 2003; 17:197-203.
19. Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose. Eur J Nucl Med Mol Imaging 2002; 29:797-803.
20. Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27:235-238.
21. Torizuka T, Kanno T, Futatsubashi M, Okada H, Yoshikawa E, Nakamura F, et al. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET. J Nucl Med 2003; 44:1051-1056.
22. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987; 60:2035-2041.
23. Faught W, Krepart GV, Lotocki R, Heywood M. Should selective paraaortic lymphadenectomy be part of surgical staging for endometrial cancer? Gynecol Oncol 1994; 55:51-55.
24. Hording U, Hansen U. Stage I endometrial carcinoma: a review of 140 patients primarily treated by surgery only. Gynecol Oncol 1985; 22:51-58.
25. Larson DM, Connor GP, Broste SK, Krawisz BR, Johnson KK. Prognostic significance of gross myometrial invasion with endometrial cancer. Obstet Gynecol 1996; 88:394-398.
26. Hamilton CA, Liou WS, Osann K, Berman ML, Husain A, Teng NN, et al. Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys 2005; 63:839-844.
27. Ito K, Kato T, Ohta T, Tadokoro M, Yamada T, Ikeda M, et al. Fluorine-18 fluoro-2-deoxyglucose positron emission tomography in recurrent rectal cancer: relation to tumour size and cellularity. Eur J Nucl Med 1996; 23:1372-1377.
28. Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Ojima H, et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of oesophageal carcinoma. Cancer 2002; 94:921-928.
29. Higashi K, Ueda Y, Ayabe K, Sakurai A, Seki H, Nambu Y, et al. FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun 2000; 21:707-714.
30. 18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study. J Nucl Med 2005; 46:267-273.
31. Buck AK, Schirrmeister H, Mattfeldt T, Reske SN. Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging 2004; 31(suppl 1):S80-S87.
32. Higashi K, Ueda Y, Sakurai A, Wang XM, Xu L, Murakami M, et al. Correlation of Glut-1 glucose transporter expression with [18F]FDG uptake in non-small cell lung cancer. Eur J Nucl Med 2000; 27:1778-1785.
33. Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 2003; 64:227-237.
34. Rodriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995; 36:1790-1796.
35. Wang BY, Kalir T, Sabo E, Sherman DE, Cohen C, Burstein DE. Immunohistochemical staining of GLUT1 in benign, hyperplastic, and malignant endometrial epithelia. Cancer 2000; 88:2774-2281.